LDLing-Lin Dai

Ling-Lin Dai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ling-Lin Dai has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Rong Tang

    Laboratory of Chinese Herbal Drug Discovery, Tropical Medicine Institute, Guangzhou University of Chinese Medicine, Guangzhou 510405, China

    1 shared publication
  • Ru-Hua Tian

    Laboratory of Chinese Herbal Drug Discovery, Tropical Medicine Institute, Guangzhou University of Chinese Medicine, Guangzhou 510405, China

    1 shared publication
  • Rui-Jing Zhu

    Laboratory of Chinese Herbal Drug Discovery, Tropical Medicine Institute, Guangzhou University of Chinese Medicine, Guangzhou 510405, China

    1 shared publication
  • Xiang-Ying Ai

    Laboratory of Chinese Herbal Drug Discovery, Tropical Medicine Institute, Guangzhou University of Chinese Medicine, Guangzhou 510405, China

    1 shared publication
  • Xiao-Ling Shen

    Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

    1 shared publication
  • Ying-Jie Hu

    Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China

    1 shared publication

Latest Publications

  • Open Access

    Total Aglycones from Marsdenia tenacissima Increases Antitumor Efficacy of Paclitaxel in Nude Mice

    by Rui-Jing Zhu, Xiao-Ling Shen, Ling-Lin Dai, Xiang-Ying Ai, Ru-Hua Tian, Rong Tang, Ying-Jie Hu

    Marsdeniae tenacissimae Caulis (MTC) is a Chinese herbal medicine used mainly for treatment of cancer, whose pharmacologically active constituents responsible for its in vivo activity and clinical efficacy have not been clearly elucidated. In this study, total aglycones of MTC (ETA) showed the ability to sensitize KB-3-1, HeLa, HepG2 and K562 cells to paclitaxel treatment. More inspiringly, ETA markedly enhanced the antitumor activity of paclitaxel in nude mice bearing HeLa or KB-3-1 xenografts. Compared to treatment with paclitaxel alone, treatment with combination of paclitaxel and ETA achieved significant reduction in volume and weight of HeLa tumors (p < 0.05), and remarkable inhibition to the growth of KB-3-1 tumors (p < 10−6). ETA was characterized by the presence of a group of tenacigenin B ester derivatives, among which four reference compounds, 11α-O-tigloyl-12β-O-acetyltenacigenin B, 11α,12β-di-O-tigloyltenacigenin B, 11α-O-2-methylbutanoyl-12β-O-tigloyltenacigenin B, and 11α-O-(2-methylbutanoyl)-12β-O-benzoyltenacigenin B, accounted for 42.14% of the total peak area of 19 detectable components assayed by HPLC. Our study has identified ETA as a promising sensitizer for cancer chemotherapy.